Gastrointestinal cancer. Malignant neoplasm of stomach
Conditions
Interventions
Intervention group: Mistletoe extract(Iscador Qu) s.c., applied three times weekly on day 2, 4 and 6 after chemotherapy between 7:00 and 9:00 a.m.The maximum applied dose will be determined by titrati
Sponsors
Avicenna-MC
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age: 18 to 80 years Voluntary written informed consent given prior to inclusion in this clinical trial Histologically confirmed (without T0, Tis, T1mic) invasive stage 4 adenocarcinoma of the stomach or pancreas
Exclusion criteria
Exclusion criteria: Assured allergy to mistletoe-containing products Co-morbidity with one of the following: hyperthyroidism and autoimmune diseases Current or during last 6 month use of immunostimulant or immunosuppressive agents except therapeutics within the routinely administered standard therapy Pregnancy or breast feeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of life assessed by EORTC QLQ-C30 questionnaire. Timepoint: Month 0 (baseline) then monthly for 6 month. Method of measurement: EORTC QLQ-C30 questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Effects of Iscador in tumor progression. Timepoint: Assessed at screening and after 6 month of therapy. Method of measurement: Computer-tomography according to RECIST criteria. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHamidreza Jalalian
Bagheiat-allah University of Medical Sciences
Outcome results
None listed